Judges Scientific warns on year ahead
Shares in Judges Scientific, the Sussex based manufacturer of scientific instruments, fell despite the company saying it expects adjusted earnings per share for 2011 to be ahead of the consensus forecast.
Shares in Judges Scientific, the Sussex based manufacturer of scientific instruments, fell despite the company saying it expects adjusted earnings per share for 2011 to be ahead of the consensus forecast.
Investors were evidently concerned over the firm's warning that the year ahead remains uncertain.
"Operations were satisfactory throughout the year and good progress was recorded in sales, profitability and cash conversion," the firm said.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
"The global economic outlook remains difficult and the year ahead promises much uncertainty. Thankfully our sector has remained relatively sheltered from the general despondency, particularly in the Far East, which accounts for a significant proportion of our sales.
"With a solid order book, a strong balance sheet and a number of new or updated products, the directors are confident that the group is well equipped for 2012."
The share price fell 1.76% to 417.5p by 13:08.
NR
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
-
Is the Office for National Statistics in turmoil?
Britain’s statistics authority, the Office for National Statistics, is increasingly unfit for purpose. Why, and what can be done?
By Simon Wilson Published
-
Saba Capital and Boaz Weinstein respond to investment trusts
As investment trust managers and industry experts accuse Saba of self-motivated opportunism, the hedge fund responds to specific "misleading claims" and sets out its stall
By Dan McEvoy Published